Filing excerpt
Veppanu (vepdegestrant)(a) Treatment of adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy May 2026 (U.S.)